%D9%85%D8%B1%D8%B6_%D8%AA%D9%83%D8%A7%D8%AB%D8%B1_%D9%86%D9%82%D9%88%D9%8AMyeloproliferative_NeoplasieMyeloproliferative_neoplasmS%C3%ADndrome_mieloproliferativo_cr%C3%B3nico%D9%86%D8%A6%D9%88%D9%BE%D9%84%D8%A7%D8%B3%D9%85_%D8%A8%DB%8C%D8%B4%E2%80%8C%D8%AA%DA%A9%D8%AB%DB%8C%D8%B1%DB%8C_%D9%85%D8%BA%D8%B2_%D8%A7%D8%B3%D8%AA%D8%AE%D9%88%D8%A7%D9%86Syndrome_my%C3%A9loprolif%C3%A9ratif%D7%9E%D7%97%D7%9C%D7%94_%D7%9E%D7%99%D7%99%D7%9C%D7%95%D7%A4%D7%A8%D7%95%D7%9C%D7%99%D7%A4%D7%A8%D7%98%D7%99%D7%91%D7%99%D7%AAMijeloproliferativne_novotvorinePenyakit_mieloproliferatifSindrome_mieloproliferativa%E9%AA%A8%E9%AB%84%E5%A2%97%E6%AE%96%E6%80%A7%E8%85%AB%E7%98%8DMieloproliferacin%C4%97_neoplazijaMyeloproliferatieve_aandoeningZespo%C5%82y_mieloproliferacyjneNeoplasia_mieloproliferativaMyeloproliferativa_neoplasierMjeloproliferacyjno_skupinaQ1898104%E9%AA%A8%E9%AB%93%E5%A2%9E%E6%AE%96%E6%80%A7%E7%96%BE%E7%97%85
about
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer (1999-10-31)Combination Chemotherapy in Treating Patients With Advanced Cancer (1998-01-31)Bone Marrow Transplantation in Treating Patients With Hematologic Cancer (1999-10-31)Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm PatientsIvosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid LeukemiaDecitabine With Ruxolitinib or Fedratinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsCombined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 MutationValue of CD26 Positive Leukemic Stem Cell in Myeloproliferative NeoplasmA Study of TQ05105 Tablets in Subjects With Myeloproliferative NeoplasmsPatient-Reported Outcomes in PHiladelphia-nEgative Cytogenetic mYeloproliferative Neoplasms (PROPHECY).Myeloproliferative Neoplasms (MPN) and COVID-19COVID-19 Epidemic and Patients With Myeloproliferative Neoplasias
P1050
P3356
P4044
Bone marrow micrometastases and circulating tumor cells: current aspects and future perspectives.Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsThe Hematopoietic Niche in Myeloproliferative NeoplasmsCirculating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic InterestHSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative NeoplasmsCytokine Regulation of Microenvironmental Cells in Myeloproliferative NeoplasmsThe Hen or the Egg: Inflammatory Aspects of Murine MPN ModelsThe Role of Reactive Oxygen Species in Myelofibrosis and Related NeoplasmsInflammation as a Driver of Clonal Evolution in Myeloproliferative NeoplasmImpact of Inflammation on Myeloproliferative Neoplasm Symptom DevelopmentPathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic InflammationMyeloid malignancies: mutations, models and managementNovel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1Monitoring Minimal Residual Disease in the Myeloproliferative Neoplasms: Current Applications and Emerging ApproachesMouse models of myeloproliferative neoplasms: JAK of all gradesGM-CSF Autoantibody-positive Pulmonary Alveolar Proteinosis with Simultaneous Myeloproliferative NeoplasmMicroangiopathic hemolytic anemia as the first manifestation of metastatic signet ring cell carcinoma of unknown origin: a case report and review of literature.Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinibRuxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasmsChildhood rhabdomyosarcoma metastatic to bone marrow presenting with disseminated intravascular coagulation and acute tumour lysis syndrome: review of the literature apropos of two cases.Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.JAK2 V617F: a single mutation in the myeloproliferative group of disordersMastocytosis: a mutated KIT receptor induced myeloproliferative disorderThe erythropoietin receptor: its role in hematopoiesis and myeloproliferative diseases.Bone marrow micrometastasis in breast cancer: review of detection methods, prognostic impact and biological issues.Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Deactylase inhibition in myeloproliferative neoplasms.Physical Activity as a Nonpharmacological Symptom Management Approach in Myeloproliferative Neoplasms: Recommendations for Future Research.PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.Epigenetics in Myeloproliferative Neoplasms.Novel molecular mechanism of cellular transformation by a mutant molecular chaperone in myeloproliferative neoplasms.Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.Defining the thrombotic risk in patients with myeloproliferative neoplasms.Successful treatment of primary bone marrow Hodgkin lymphoma with brentuximab vedotin: a case report and review of the literature.Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine useClassical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitorsThe ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
P921
description
Gruppe von Bluterkrankungen
@de
hematopoietic disorders that derive from the blood-forming stem cells of the bone marrow
@en
kemik iliği hastalığı
@tr
name
Mieloproliferacinės neoplazijos
@lt
Mjeloproliferacyjno skupina
@szl
Myeloproliferative Erkrankung
@de
Penyakit mieloproliferatif
@id
Sindrome mieloproliferativa
@it
Zespoły mieloproliferacyjne
@pl
beinmergskreft
@nn
canser mêr yr esgyrn
@cy
càncer de medul·la òssia
@ca
mijeloproliferativna novotvorina
@hr
type
label
Mieloproliferacinės neoplazijos
@lt
Mjeloproliferacyjno skupina
@szl
Myeloproliferative Erkrankung
@de
Penyakit mieloproliferatif
@id
Sindrome mieloproliferativa
@it
Zespoły mieloproliferacyjne
@pl
beinmergskreft
@nn
canser mêr yr esgyrn
@cy
càncer de medul·la òssia
@ca
mijeloproliferativna novotvorina
@hr
altLabel
Myeloid neoplasm (morphologic abnormality)
@en
Myeloproliferatie
@nl
Myeloproliferatief
@nl
Myeloproliferatieve aandoeningen
@nl
Myeloproliferatieve
@nl
Myeloproliferative disease NOS
@en
Myeloproliferative disease, NOS
@en
Myeloproliferative disease, no ICD-O subtype (morphologic abnormality)
@en
Myeloproliferative diseases, MPDs
@en
Myeloproliferative disorder (morphologic abnormality)
@en
prefLabel
Mieloproliferacinės neoplazijos
@lt
Mjeloproliferacyjno skupina
@szl
Myeloproliferative Erkrankung
@de
Penyakit mieloproliferatif
@id
Sindrome mieloproliferativa
@it
Zespoły mieloproliferacyjne
@pl
beinmergskreft
@nn
canser mêr yr esgyrn
@cy
càncer de medul·la òssia
@ca
mijeloproliferativna novotvorina
@hr
P279
P2888
P493
P486
P6366
P646
P672
P1375
P1692
P1748
P1995
P2892
P31
P3827
myeloproliferative-disorders
P3841
HP:0005547
P4229
P486
P493
P5270
MONDO:0005374
P6366
2781107747
2908884530